Table of contents
- Original news
- What are the key changes being proposed in the Clinical Trials Regulation?
- Would the introduction of these proposals be a desirable development?
- Are there any possible drawbacks to the changes?
- What effect could the changes have on pharmaceutical companies and lawyers practising in this area?
- Any predictions for future developments?
Article summary
Medical law analysis: Are we one step closer to consistency in the approach to clinical trials across the EU? Dr Peter Feldschreiber, barrister at 4 New Square, looks at the Clinical Trials Regulation and what it means for the development of new medicines in the EU.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial